KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Accumulated Expenses: 2009-2024

Historic Accumulated Expenses for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $378.7 million.

  • Acadia Pharmaceuticals' Accumulated Expenses rose 3.07% to $334.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $334.8 million, marking a year-over-year increase of 3.07%. This contributed to the annual value of $378.7 million for FY2024, which is 59.97% up from last year.
  • As of FY2024, Acadia Pharmaceuticals' Accumulated Expenses stood at $378.7 million, which was up 59.97% from $236.7 million recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Accumulated Expenses ranged from a high of $378.7 million in FY2024 and a low of $89.2 million during FY2021.
  • Its 3-year average for Accumulated Expenses is $242.8 million, with a median of $236.7 million in 2023.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first dropped by 8.50% in 2021, then spiked by 109.69% in 2023.
  • Yearly analysis of 5 years shows Acadia Pharmaceuticals' Accumulated Expenses stood at $97.5 million in 2020, then fell by 8.50% to $89.2 million in 2021, then grew by 26.56% to $112.9 million in 2022, then surged by 109.69% to $236.7 million in 2023, then spiked by 59.97% to $378.7 million in 2024.